Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study.
Allyson J. Ocean
Research Funding - Immunomedics
Michael J. Guarino
Research Funding - Immunomedics
Kenneth Lee Pennington
Research Funding - Immunomedics
Gregory M. Springett
Research Funding - Immunomedics
Seza A Gulec
Research Funding - Immunomedics
Tanios S. Bekaii-Saab
Research Funding - Immunomedics
Alberto J. Montero
Research Funding - Immunomedics
Edith P. Mitchell
Research Funding - Immunomedics
John S Kauh
Research Funding - Immunomedics
Max W. Sung
Research Funding - Immunomedics
David V. Gold
No relevant relationships to disclose
Heather Horne
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
William A. Wegener
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
David M. Goldenberg
Employment or Leadership Position - Immunomedics (B)
Stock Ownership - Immunomedics (B)